The United Kingdom and the United States have established a landmark trade agreement that will guarantee zero tariffs on British pharmaceutical shipments being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial products will remain at zero for a timeframe of three years.
This agreement comes after earlier threats to significantly raise import taxes on branded drug products, with increases floated as high as double the cost.
"This arrangement between the Britain bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. medicine commerce," an announcement declared.
Commercial Significance
Medicines are one of the UK's largest export categories to the US, which is by far the largest market for major UK drugmakers.
Statistics reveal that in the year leading up to September, the UK sold medicines totaling £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that timeframe.
"This guarantee protects employment, stimulates funding and sets the stage for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Specific NHS Changes
The deal involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, repayments exceeded 20%.
Broader Context
The deal comes amid a protracted tension between the drug companies and the British authorities over drug pricing and NHS adoption.
This friction were heightened by assertions that American patients were charged significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
